Bristol Myers Squibb (CELG-RI) Research & Development (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Research & Development data on file, last reported at $2.6 billion in Q1 2026.

• Research & Development for Q1 2026 came in at $2.6 billion, up 17.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.3 billion (down 3.53% YoY), and the FY2025 annual result was $10.0 billion, down 10.83% from the prior year.
• Research & Development advanced to $2.6 billion in Q1 2026 per CELG-RI's latest filing, from $2.6 billion in the prior quarter.
• Over five years, Research & Development peaked at $3.2 billion in Q4 2024 and troughed at $2.2 billion in Q3 2023.
• A 5-year average of $2.5 billion and a median of $2.5 billion in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development advanced 28.77% in 2024, then retreated 18.96% in 2025.
• A 5-year view of Research & Development shows it stood at $2.5 billion in 2022, then dropped by 1.27% to $2.5 billion in 2023, then increased by 28.77% to $3.2 billion in 2024, then dropped by 18.96% to $2.6 billion in 2025, then rose by 2.44% to $2.6 billion in 2026.
• Business Quant data shows CELG-RI's Research & Development at $2.6 billion in Q1 2026, $2.6 billion in Q4 2025, and $2.5 billion in Q3 2025.